Literature DB >> 27706619

Assessing the association between EFEMP1 rs3791679 polymorphism and risk of glioma in a Chinese Han population.

N Jiang1,2, Y P Peng3, X Y Wang2, C W Dou4, W M He1.   

Abstract

In this study, we assessed the association between the EFEMP1 rs3791679 polymorphism and glioma risk in a Chinese Han population. A total of 94 glioma patients and 206 healthy controls who conformed to the inclusion and exclusion criteria were recruited from Baogang Hospital between March 2012 and October 2014. The EFEMP1 rs3791679 gene polymorphism was assessed using a polymerase chain reaction-restriction fragment length polymorphism assay and the results were statistically analyzed using SPSS Statistics 17.0. The results of unconditional logistic regression analysis revealed that the GG genotype of EFEMP1 rs3791679 was positively correlated with increased susceptibility to glioma (adjusted OR = 2.09, 95%CI = 1.21-7.81). Moreover, the GG genotype of EFEMP1 rs3791679 was correlated with higher risk of glioma compared to the AA+GA genotype (OR = 2.60, 95%CI = 1.08-6.28) in the regressive model. In conclusion, we report that the EFEMP1 rs3791679 polymorphism influences glioma susceptibility in the Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27706619     DOI: 10.4238/gmr.15038279

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  3 in total

1.  The associations between common SNPs of EFEMP1 gene and glioma risk in Chinese population.

Authors:  Jun Hu; Dong Dong; Dandan Lu
Journal:  Onco Targets Ther       Date:  2017-11-06       Impact factor: 4.147

2.  Associations between EGFR gene polymorphisms and susceptibility to glioma: a systematic review and meta-analysis from GWAS and case-control studies.

Authors:  Xiao Yu; Nian Rong Sun; Hai Tao Jang; Shi Wen Guo; Min Xue Lian
Journal:  Oncotarget       Date:  2017-09-18

3.  Impact of AKAP6 polymorphisms on Glioma susceptibility and prognosis.

Authors:  Ming Zhang; Yonglin Zhao; Junjie Zhao; Tingqin Huang; Yuan Wu
Journal:  BMC Neurol       Date:  2019-11-23       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.